Progressive Multifocal Leukoencephalopathy (PML) Drug Development Pipeline Study, H2 2018

August 2018 | 35 pages | ID: PC46AB4E9F5EN
VPAResearch

Abstracts

Progressive Multifocal Leukoencephalopathy (PML) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Progressive Multifocal Leukoencephalopathy (PML) pipeline products.

DISEASE OVERVIEW

Progressive multifocal leukoencephalopathy (PML) is a rare but life-threatening condition, which is an infection of central nervous system. It is caused by human polyoma virus JC virus, which damages oligodendrocytes, resulting in nerve demylenation. Recently, patients undergoing immunotherapy are being reported to undergo Progressive multifocal leukoencephalopathy (PML).

Disease symptoms vary with the status of the disease ranging from gradual to worsening with time. Ataxia, paralysis, vision and speech problems and Coma are typical symptoms of PML.

Seven companies are actively developing new clinical compounds for administering patients with Progressive multifocal leukoencephalopathy. These companies include%li%Excision BioTherapeutics Inc, Forge Life Science LLC, Inhibikase Therapeutics Inc, Neurimmune Holding AG, Neuway Pharma GmbH, Pomona Ricerca SRL and Vir Biotechnology Inc.

REPORT DESCRIPTION

The Progressive Multifocal Leukoencephalopathy (PML) pipeline guide presents complete overview of drugs currently being developed for Progressive Multifocal Leukoencephalopathy (PML). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Progressive Multifocal Leukoencephalopathy (PML) pipeline candidate.

Research and Development progress along with latest news related to each of the Progressive Multifocal Leukoencephalopathy (PML) pipeline candidates is included.

Major companies participating in therapeutic development of Progressive Multifocal Leukoencephalopathy (PML) are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Progressive Multifocal Leukoencephalopathy (PML) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Progressive Multifocal Leukoencephalopathy (PML) clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Progressive Multifocal Leukoencephalopathy (PML) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) PIPELINE REPORT INCLUDES

• Panorama of Progressive Multifocal Leukoencephalopathy (PML) pipeline markets including statistics on therapeutic drugs and companies involved
• Progressive Multifocal Leukoencephalopathy (PML) Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
• Progressive Multifocal Leukoencephalopathy (PML) pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in Progressive Multifocal Leukoencephalopathy (PML) pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Progressive Multifocal Leukoencephalopathy (PML) pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire Progressive Multifocal Leukoencephalopathy (PML) pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Progressive Multifocal Leukoencephalopathy (PML) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Progressive Multifocal Leukoencephalopathy Pipeline include-
  Number of Companies with Progressive Multifocal Leukoencephalopathy projects in pre-clinical Development-
  Number of Companies with Progressive Multifocal Leukoencephalopathy projects in Clinical Development-
  Progressive Multifocal Leukoencephalopathy Pipeline Companies based in Americas
  Progressive Multifocal Leukoencephalopathy Pipeline Companies based in Europe
  Progressive Multifocal Leukoencephalopathy Pipeline Companies based in Asia Pacific
  Progressive Multifocal Leukoencephalopathy Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
  Progressive Multifocal Leukoencephalopathy Pipeline Agents in pre- clinical/Discovery stage of Development
  Progressive Multifocal Leukoencephalopathy Pipeline Agents in Clinical Development stage
  Progressive Multifocal Leukoencephalopathy Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs-
  Small molecules among the Progressive Multifocal Leukoencephalopathy Pipeline agents

II. INSIGHTS INTO PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY PIPELINE

1. Disease Overview
  Introduction to Progressive Multifocal Leukoencephalopathy
  Symptoms and Causes of Progressive Multifocal Leukoencephalopathy
  Treatment or Prevention Options for Progressive Multifocal Leukoencephalopathy
  Other Details
2. Phase wise Pipeline Compounds
  Progressive Multifocal Leukoencephalopathy Pipeline- Pre- Clinical/Discovery stage Drugs
  Progressive Multifocal Leukoencephalopathy Pipeline- Phase 1 stage Drugs
  Progressive Multifocal Leukoencephalopathy Pipeline- Phase 2 stage Drugs
  Progressive Multifocal Leukoencephalopathy Pipeline- Phase 3 stage Drugs
  Progressive Multifocal Leukoencephalopathy Pipeline- Pre-Registration stage Drugs
3. Company wise Progressive Multifocal Leukoencephalopathy Pipeline Compounds
4. Progressive Multifocal Leukoencephalopathy Pipeline by Mechanism of Action

III. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY PIPELINE COMPOUND DETAILS

EBT103
sirtuin-targeted drugs Viral Infections
IkT-1427
NI-307
NWP007
PN-JC
Monoclonal Antibody for JCV linked PML
Drug Details
1. Snapshot
  Name of the Therapeutic Agent
  Originator
  Developing Company
  Co-Developer/License Partner
  Orphan Drug/Fast Track/Designation
  Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY PIPELINE COMPANY BRIEFS

Excision BioTherapeutics Inc
Forge Life Science LLC
Inhibikase Therapeutics Inc
Neurimmune Holding AG
Neuway Pharma GmbH
Pomona Ricerca SRL
Vir Biotechnology Inc

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY PIPELINE MARKET

VI. APPENDIX

1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability